|
WO2020214739A1
|
|
Methods and compositions for treating inflammatory diseases
|
|
WO2020077010A1
|
|
Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders
|
|
US2020140925A1
|
|
Methods for validation of microbiome sequence processing and differential abundance analyses via multiple bespoke spike-in mixtures
|
|
EP3810798A2
|
|
Anaerostipes hadrus for use in promoting health
|
|
EP3773644A1
|
|
Proteins for the treatment of epithelial barrier function disorders
|
|
WO2019099509A1
|
|
Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder
|
|
EP3688196A1
|
|
Gemella sanguinis as a biotherapeutics
|
|
CN111050782A
|
|
Streptococcus australis as biotherapy
|
|
AU2018309153A1
|
|
Roseburia hominis, Eubacterium eligens, and combinations thereof as biotherapeutics
|
|
WO2018223051A1
|
|
Proteins for the treatment of epithelial barrier function disorders
|
|
WO2018213679A1
|
|
Proteins for the treatment of epithelial barrier function disorders
|
|
US2020061152A1
|
|
Proteins for the treatment of epithelial barrier function disorders
|
|
AU2018248324A1
|
|
Proteins for the treatment of epithelial barrier function disorders
|
|
KR20190140925A
|
|
Leveraging Sequence-Based Fecal Microbial Community Survey Data to Identify Complex Biomarkers for Colorectal Cancer
|
|
CA2899808A1
|
|
Microbial ecology shift assay
|
|
EP2941259A1
|
|
Microbiome modulation index
|
